Eupraxia Pharmaceuticals Files 6-K with Press Release
Ticker: EPRX · Form: 6-K · Filed: Jun 6, 2024 · CIK: 1581178
Sentiment: neutral
Topics: filing, regulatory, registration-statement
TL;DR
Eupraxia filed a 6-K with a press release and voting report, incorporating into F-10 and S-8 filings.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on June 6, 2024, reporting a press release dated June 6, 2024, and a report of voting. This filing incorporates Exhibit 99.2 into its Registration Statements on Form F-10 (File No. 333-276586) and Form S-8 (File No. 333-278534).
Why It Matters
This filing provides updates and incorporates information into existing registration statements, which is crucial for ongoing investor awareness and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily incorporates previously issued information and updates registration statements, indicating no new material negative events.
Key Numbers
- 001-41923 — SEC File Number (Identifies the company's filing history with the SEC.)
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Registrant
- June 6, 2024 (date) — Filing and Press Release Date
- 333-276586 (document_id) — Form F-10 Registration Statement File Number
- 333-278534 (document_id) — Form S-8 Registration Statement File Number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a press release dated June 6, 2024, and a report of voting, and to incorporate Exhibit 99.2 into the company's existing registration statements.
Which registration statements are being updated by this filing?
This filing incorporates Exhibit 99.2 into the company's Registration Statement on Form F-10 (File No. 333-276586) and its Registration Statement on Form S-8 (File No. 333-278534).
What date is associated with the press release mentioned in the filing?
The press release mentioned in the filing is dated June 6, 2024.
What type of company is Eupraxia Pharmaceuticals Inc. according to the filing?
Eupraxia Pharmaceuticals Inc. is classified under Standard Industrial Classification code 2834, which is Pharmaceutical Preparations.
Where are Eupraxia Pharmaceuticals Inc.'s principal executive offices located?
The company's principal executive offices are located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada.
Filing Stats: 209 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2024-06-06 17:01:07
Filing Documents
- form6k.htm (6-K) — 12KB
- ex991.htm (EX-99.1) — 21KB
- ex992.htm (EX-99.2) — 19KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-000706.txt ( ) — 86KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: June 6, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer